Introduction
============

Intervertebral disc (ID) herniation is a common, yet poorly understood disorder. Behavioral, hereditary and environmental factors cumulatively affect the nutrition and homeostasis of the disc, ultimately resulting in its structural breakdown and in the occurrence of herniation. The incidence of symptomatic lumbar ID herniation in the United States is estimated at 1--2%, for which approximately 200,000 discectomies are performed annually ([@b1-mmr-15-04-2195]). The direct costs for conservative or surgical treatment and he indirect costs deriving from the loss of productivity are enormous ([@b2-mmr-15-04-2195]).

However, ID herniation is considered to present a favorable natural history. Sequential magnetic resonance imaging (MRI) studies have documented that the majority of disc herniations diminish in size ([@b3-mmr-15-04-2195]). Saal *et al* reported that almost 80% of disc herniations treated non-operatively decreased by \>50% in follow-up examinations ([@b4-mmr-15-04-2195]). In addition, a positive correlation has been found between the regression of disc herniation and the remission of symptoms ([@b3-mmr-15-04-2195],[@b4-mmr-15-04-2195]). Various molecules, such as pro-inflammatory cytokines, growth factors (GFs) and matrix metalloproteinases (MMPs) have been implicated in the mechanisms that regulate ID degradation and herniation, as well as the spontaneous resorption of herniated disc fragments ([@b5-mmr-15-04-2195]).

GFs are polypeptides involved in the modulation of cell growth and differentiation that exert their biologic effects through endocrine, paracrine and autocrine pathways ([@b6-mmr-15-04-2195]). Over 18 different GFs have been identified, including vascular endothelial growth factor (VEGF), transforming growth factor β1 (TGF-β1), basic fibroblast growth factor (bFGF)-2, platelet derived growth factor (PDGF), epidermal growth factor (EGF) and insulin growth factor-1 (IGF-1). The PDGF family in particular is formed by the PDGF-A, -B, -C and -D isoforms that are encoded by four genes located at different chromosomes and may form homodimers, as well as heterodimers. These molecules signal through two cell-surface receptors, PDGF-Rα and β ([@b7-mmr-15-04-2195]).

To date, the expression of various GFs in the degenerate and herniated ID has been investigated in numerous studies. The increased protein expression of IGF-1, FGF-2, VEGF, PDGF and TGF-β has been found by means of immunohistochemistry ([@b8-mmr-15-04-2195]--[@b11-mmr-15-04-2195]). The transcript levels of TGF-β and VEGF have also been examined in human ID herniation specimens ([@b12-mmr-15-04-2195]). Consequently, preliminary studies have examined the effect of administering different GFs on ID physiology and degeneration *in vitro* and *in vivo* ([@b13-mmr-15-04-2195],[@b14-mmr-15-04-2195]). However, a simultaneous assessment of the molecular profile of numerous GFs in human herniated IDs has not been performed to date, at least to the best of our knowledge. In addition, clinical and epidemiological determinants, such as the extent of disc herniation, the duration and intensity of symptoms, age and employment may considerably affect the pathophysiology of ID degeneration and the potential for regression of herniated ID fragments. The association between the clinical, epidemiological and molecular profile of ID herniation would potentially provide valuable insight into the biology and clinical course of the disorder. Therefore, the purpose of the present study was to simultaneously examine the molecular profiles of numerous GFs by means of reverse transcriprtion-quantitative polymerase chain reaction (RT-qPCR), and to investigate potential correlations with the clinical and epidemiological characteristics of patients suffering from lumbar ID herniation.

Materials and methods
=====================

### Tissue samples

ID tissue samples were collected from a total of 63 patients who underwent posterior open discectomy for lumbar ID herniation in our department during a recruitment period of one year (2008). The patients reported symptoms of radiculopathy prior to surgery. Patients suffering from spinal stenosis, spondylolisthesis, scoliosis or systemic inflammatory disorders were excluded from the study. After excision, an experienced pathologist, in addition to the clinicians present, examined the tissue samples and identified the pulposus sections in order to limit the percentage of end-plates or annulus. Samples were then immediately refrigerated at −80°C until RNA extraction. Ten cadaveric ID tissue samples were also obtained within 12 h of the patient succumbing to the disease, referring to various diseases other than ID herniation. The samples were used as controls of normal growth factor mRNA expression. Donors were aged between 20 and 46 years and were known to have a negative history of lower back pain, spinal trauma or systemic inflammatory disease. All the patients or relatives signed an informed consent form approved by the University Ethics Committee to participate in the present study. The study design was in accordance with the Declaration of Helsinki Guidelines.

Prior to surgery, the patients routinely underwent an MRI examination for the classification of ID herniation. The recommendations of the combined task force from the North American Spine Society, the American Society of Spine Radiology and the American Society of Neuroradiology based on the imaging characterization of Milette ([@b15-mmr-15-04-2195]) were used to determine the type of ID herniation. Pre-operative pain intensity was measured subjectively using the visual analogue scale score (VAS). Patient employment was defined as heavy if it included manual labour with repetitive loading of the spine. A summary of patient and control group baseline data is presented in [Table I](#tI-mmr-15-04-2195){ref-type="table"}. There were no significant differences in terms of age, gender, body mass index (BMI), employment and smoking habits between the control and ID herniation groups (minimum P=0.24).

### RNA extraction and RT-qPCR

Total RNA was isolated from fresh tissue and homogenized with a power homogenizer using TRIzol reagent (Invitrogen, Carlsbad, CA, USA). RNA concentration and purity were determined on a UV spectrophotometer (Hitachi Instruments Inc., San Jose, CA, USA) by absorbance measurements (260 nm absorbance and 260/280 nm absorbance ratio). RNA integrity was examined by 1% agarose gel electrophoresis and ethidium bromide staining.

Reverse transcription reactions for the preparation of first-strand cDNA from 2 µg of total RNA were performed using the AffinityScript™ Multi Temperature cDNA synthesis kit (Stratagene, La Jolla, CA, USA). Random hexamers were used as amplification primers. Quantitative PCR (qPCR) reactions were performed using the Mx3000P real-time PCR system with SYBR^®^-Green I Master Mix (both from Stratagene). Data were collected and analyzed using the Mx3000P real-time PCR software version 2.00, Build 215 Schema 60 (Stratagene). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as an internal control to normalize the mRNA expression levels of the GFs examined. The primer pair sequences used are listed in [Table II](#tII-mmr-15-04-2195){ref-type="table"}. PCR products were analyzed by electrophoresis on 2% agarose gels, stained with ethidium bromide and photographed on a UV light transilluminator. GF transcription levels were calculated using the following formula: normalized sample or control = (1 + E~GF~)^−∆∆Cq^GF/(1 + E~GAPDH~)^−∆∆Cq^GAPDH. Procedures were repeated with a cDNA template, synthesized three times from the same RNA. The mRNA levels of each sample for each gene tested represent the mean value of data acquired from three independent RT-qPCR experiments. The reproducibility of the RT-qPCR results for the same samples was 99%.

### Statistical analysis

The one-sample Kolmogorov-Smirnov test was used to assess the normality of the distribution of the mRNA expression values for the genes studied. Accordingly, the mRNA expression levels of the GFs examined in the control and herniated groups were compared using parametric and non-parametric procedures, respectively. Differences in GF expression between herniated and control IDs and between subgroups of different clinical characteristics were examined using parametric (one-way and repeated measures ANOVA) and non-parametric (Kruskal-Wallis and Mann-Whitney) tests accordingly. Pairwise comparisons were performed to further explore the interaction. Categorical variables were compared with the use of χ^2^ test. The Spearman rank correlation test (non-parametric) was also employed to examine pair-wise correlations in growth factor mRNA expression in control and herniated discs. The significance level was set at P\<0.05. Statistical calculations were performed using SPSS software, version 15 (SPSS, Inc., Chicago, IL, USA).

Results
=======

### GF mRNA levels in normal and herniated discs

The transcript levels of the GFs examined were not significant between the control and ID herniation groups (minimum P=0.26, Mann-Whitney test, [Table III](#tIII-mmr-15-04-2195){ref-type="table"}). With the exception of EGF that was not expressed in neither of the 2 groups, all the GFs examined were expressed in the two study groups. Specifically, the mRNA expression status (expressed or not) of the genes examined ranged from 40 to 100% in the controls and 35 to 100% in the ID herniation groups ([Table III](#tIII-mmr-15-04-2195){ref-type="table"}). PDGF-C and -D mRNA expression was observed in all the herniated IDs, while IGF was the least commonly expressed in the same group (34.9%).

### Pair-wise GF mRNA co-expression analysis

Pair-wise correlations between the genes examined in the ID herniation groups and the controls are presented in [Tables IV](#tIV-mmr-15-04-2195){ref-type="table"} and [V](#tV-mmr-15-04-2195){ref-type="table"}, respectively (Spearman correlations). Compared with the controls, an increased number of positive correlations was observed in the ID herniation group between most of the genes examined.

### Correlation of transcript levels with clinicopathological characteristics

#### Age and gender

Age did not significantly affect the mRNA expression levels of the genes examined (minimum P=0.07, Kruskal-Wallis test). Male patients exhibited increased mRNA expression levels of PDGF-C and -D compared with female patients (P=0.007 and 0.024, respectively, Mann-Whitney test) (absolute values not shown).

#### BMI

Significant negative correlations were observed between the patient BMI values and the transcript levels of VEGF, PDGFRA and PDGFRB (P=0.036, 0.037 and 0.02, respectively, Spearman correlation).

#### Duration of symptoms

The transcript levels of PDGF-C and -D were significantly affected by the duration of patient symptoms (P=0.02 and 0.05, respectively, Kruskal-Wallis test). Specifically, patients suffering from acute pain (\<3 months) exhibited an increased mRNA expression of PDGF-C compared with those suffering for 3--10 months and for \>10 months (P=0.04 and 0.01, respectively, Mann-Whitney test). Similarly, the PDGF-D expression levels were also significantly higher in patients suffering from acute (\<3 months) compared with chronic pain (P=0.017, Mann-Whitney test, [Fig. 1](#f1-mmr-15-04-2195){ref-type="fig"}).

#### Pain intensity

The intensity of patient pain significantly affected the expression levels of PDGF-B, -C and -D (P=0.044, 0.024 and 0.05, Kruskal-Wallis test). Specifically, patients experiencing moderate pain (VAS 5--7) exhibited an increased mRNA expression of PDGF-B, -C and -D compared with those with low intensity pain (VAS 0--4) (P=0.01, 0.018 and 0.05, respectively, Mann-Whitney test). In addition, patients with intense pain (VAS 8--10) also exhibited a significantly increased expression of PDGF-C and -D compared with those with low intensity pain (P=0.026 and 0.03, respectively, Mann-Whitney test, [Fig. 2](#f2-mmr-15-04-2195){ref-type="fig"}).

#### Type of ID herniation

The transcript levels of VEGF significantly correlated with the type of ID herniation (P=0.023, Kruskal-Wallis test). Specifically, ID herniation samples with protrusion exhibited an increased mRNA expression of VEGF compared with the extruded IDs (P=0.019, Mann-Whitney test, [Fig. 3](#f3-mmr-15-04-2195){ref-type="fig"}).

#### Employment

The transcript levels of the genes examined did not differ significantly between patients with either light or heavy employment (minimum P=0.15, Mann-Whitney test) (absolute values not shown).

#### Smoking

The mRNA expression levels of the GFs examined did not differ significantly between smoking and non-smoking patients (minimum P=0.087, Mann-Whitney test). Accordingly, the amount of cigarette smoking did not significantly affect the transcript levels of any of the genes studied (minimum P=0.29, Kruskal-Wallis test) (absolute values not shown).

Discussion
==========

The current study examined the molecular profiles of numerous GFs by means of RT-qPCR in surgically resected lumbar ID herniation specimens and matched controls. Correlations of GF transcript levels with the patient clinical and epidemiological characteristics were also explored. Multiple positive correlations between the GFs were identified in the group of herniated discs. The VEGF transcript levels were significantly higher in protruding compared with the extruded discs. The duration and intensity of patient symptoms significantly affected the PDGF transcript levels. BMI exhibited significant negative correlations with the transcript levels of VEGF and both PDGF-receptor isotypes (data not shown).

There have been limited reports in the literature examining the molecular profiles of GFs in ID herniation. In lumbar herniated IDs, Ahn *et al* detected TGF-β mRNA expression in 5 out of 10 specimens examined ([@b16-mmr-15-04-2195]), whereas Kontinnen *et al* found a decreased mRNA expression of the same factor ([@b12-mmr-15-04-2195]). Control groups were not included in these studies. Kontinnen *et al* also failed to identify the mRNA or protein expression of EGF, which they attributed to the reduced anabolic potential of the disc. The findings of the present study did not identify any differences in the mRNA expression of GFs in a substantial number of herniated and control ID specimens. By contrast, immunohistochemistry, has produced more variable results. Specchia *et al* reported stronger staining for IGF-1 in chondrocytes of herniated compared with control discs ([@b10-mmr-15-04-2195]). Similarly, Tolonen *et al* observed significantly stronger staining for PDGF and TGF-β in human herniated ID tissue ([@b8-mmr-15-04-2195],[@b9-mmr-15-04-2195]). Given that no differences in GF expression are evident at the mRNA level compared with the controls, these findings suggest that post-transcriptional modifications may occur in the setting of ID herniation.

The transcript levels of the GFs examined significantly correlated with each other in herniated IDs. *In vitro* experiments have demonstrated a synergistic effect of VEGF and TGF-β1 in the induction of angiogenesis ([@b17-mmr-15-04-2195]). In addition, PDGF has been found to upregulate VEGF in mural cells, thereby further enhancing angiogenesis ([@b18-mmr-15-04-2195]). IGF-I has also been shown to induce VEGF mRNA and protein expression in cultured colorectal carcinoma cells ([@b19-mmr-15-04-2195]). Most of these GFs are also under the regulatory effect of inflammatory cytokines, such as interleukin-1 (IL-1) and tumor necrosis factor-α (TNF-α). Both TNF-α and IL-1 have been shown to interact with numerous GFs in human degenerated discs and trigger a sequence of macrophage and MMP activation that potentiates the spontaneous resorption of herniated ID fragments ([@b20-mmr-15-04-2195]--[@b22-mmr-15-04-2195]). Multiple positive correlations between numerous MMPs have also been demonstrated in human ID herniation ([@b5-mmr-15-04-2195]). Our findings, therefore, confirm a synergistic activation of GFs in ID herniation as part of a metabolic cascade that ultimately promotes the regression process of herniated discs.

Our results demonstrated that the transcript levels of VEGF were significantly higher in protruding compared with extruded IDs. VEGF is a potent mitogen for vascular endothelial cells. It induces new vessel formation through cell proliferation and luminal formation and has also been found to increase blood vessel permeability ([@b23-mmr-15-04-2195]). Using immunohistochemistry, Tolonen *et al* and Koike *et al* confirmed the expression of VEGF in extruded and sequestrated human IDs ([@b9-mmr-15-04-2195],[@b24-mmr-15-04-2195]). A significant correlation was also observed between the expression of VEGF and the presence of vascular endothelial cells ([@b24-mmr-15-04-2195]). Protruding ID herniation samples were not included in these studies. Ozaki *et al* reported the presence of small blood vessels in 73.4% of herniated ID tissues examined histopathologically, regardless of hernia type ([@b25-mmr-15-04-2195]). They also suggested that neovascularization was present in the outermost annulus layers, even in protruding herniations. To the best of our knowledge, the present study is the first to confirm the expression of VEGF in protruding hernias at the mRNA level, thereby supporting the hypothesis that VEGF upregulation plays a key role even in the earliest stages of the neovascularization process that follows ID herniation.

PDGF is considered a key mediator in the tissue repair process. It stimulates mitogenicity and chemotaxis of neutrophils and macrophages in a variety of mesenchymal-derived cells, such as osteoblasts, chondrocytes and fibroblasts ([@b7-mmr-15-04-2195]). It has been shown that PDGF exerts its effect on the repair process, not by altering its normal sequence, but by increasing its rate ([@b26-mmr-15-04-2195]). It has been hypothesized that PDGF induces the production of extracellular matrix components and cellular proliferation in the ID in a similar mechanism as in the articular cartilage ([@b9-mmr-15-04-2195]). It has also been shown to participate in the resorption process of herniated ID fragments by upregulating MMP expression ([@b22-mmr-15-04-2195]). The findings of the present study indicated that the PDGF transcript levels were significantly higher in patients suffering from intense and acute pain. These findings support the role of PDGF as a key modulator of the repair process of damaged connective tissue, and indicate that it is primarily expressed in the acute phase of sciatica, during which it participates in a metabolic attempt to repair the herniated ID tissue.

Notably, PDGF isoforms -C and -D were the ones principally upregulated in patients with intense and acute pain. Among the PDGF isoforms, PDGF-BB is considered 'universal', mainly due to its ability to bind to both known forms of PDGF-receptor isotypes. In the musculoskeletal system, recombinant human PDGF-BB injection therapy has already been employed in experimental and clinical studies to promote fracture healing and foot and ankle fusion rates ([@b27-mmr-15-04-2195],[@b28-mmr-15-04-2195]). It is considered important in upregulating cytokines that enhance osseous and soft-tissue healing and regeneration. However, novel information on the biological actions of PDGF-C and -D isoforms has recently been added. PDGF-D was found to strongly attract macrophages to its expression sites and to inhibit the vascular leakage that results from growth factor-induced angiogenesis. When co-expressed with VEGF-E, it promotes the *in vitro* stability of the newly generated vessels induced by VEGF-E alone, leading to enlarged and less leaky vessels ([@b29-mmr-15-04-2195]). Both neovascularization and subsequent macrophage infiltration are critical stages of the acute repair response following ID herniation. Our findings therefore suggest a more favorable effect of PDGF-CC and -DD isoforms in the acute phase of disc herniation and potentially provide an alternative target for growth factor therapy research. PDGF-CC isoform is known to bind to PDGF-R A/A and A/B dimers, whereas PDGF-DD binds to B/B dimers. B-receptor expression was found to be low in connective tissue cells and to increase during inflammation ([@b30-mmr-15-04-2195]). In the present study, the expression of each receptor isotype was detected in approximately 50% of the herniated specimens. However, it was not significant compared with the controls.

BMI exhibited significant negative correlations with the transcript levels of VEGF and both PDGF-receptor isotypes. To the best of our knowledge, there is a paucity of data available on patient BMI in studies evaluating the molecular mechanisms implicated in ID herniation. As a consequence, BMI has not been previously associated with the expression of GFs in ID herniation. In a recent histo-morphological study, Weiler *et al* correlated histological disc alterations in surgical lumbar ID specimens with patient BMI, suggesting an accelerated course of ID degeneration in obese individuals ([@b31-mmr-15-04-2195]). Occupational and lifestyle factors, including obesity, have been implicated in the pathogenesis of ID herniation, mainly on a biomechanical basis focusing on increased loading and structural failure of the disc ([@b32-mmr-15-04-2195],[@b33-mmr-15-04-2195]). However, a metabolic pathway may also exist. The findings of this study indicated that, in the obese population, a decrease in the expression of GFs directly associated with the acute repair process and regression of herniated IDs through peripheral neovascularization and chemotaxis. A previous study demonstrated the overexpression of TNF-α in the adipose tissue of obese individuals, as well as a consequent decrease with weight loss ([@b34-mmr-15-04-2195]). In the ID, TNF-α has been shown to play a central signaling role in the metabolic cascade that regulates the natural history of degeneration and herniation by promoting the expression of other cytokines, MMPs and various GFs ([@b16-mmr-15-04-2195]). Although a clear association cannot be established solely on the available evidence, these findings imply a molecular effet, in addition to the biomechanical effect of obesity in the pathogenesis and natural history of ID herniation.

In conclusion, the present study provides evidence of the simultaneous molecular profile of numerous GFs in herniated lumbar ID surgical specimens supporting the hypothesis of growth factor involvement in the natural history of ID herniation. GFs synergistically act in herniated IDs. Increased VEGF expression possibly induces the neovascularization process in the earliest stages of ID herniation. PDGF isoforms -C and -D potentially play a role in the acute phase of radiculopathy in a metabolic response for tissue healing. A molecular effect, in addition to the biomechanical effect of obesity in the pathogenesis and natural history of ID herniation is also suggested.

![Normalized transcript levels of: (A) PDGF-C and (B) PDGF-D in regard to the duration of patient symptoms. PDGF, platelet derived growth factor.](MMR-15-04-2195-g00){#f1-mmr-15-04-2195}

![Normalized transcript levels of: (A) PDGF-B; (B) PDGF-C and (C) PDGF-D in regard to the intensity of pain experienced by the patients. PDGF, platelet derived growth factor; VAS, visual analogue scale.](MMR-15-04-2195-g01){#f2-mmr-15-04-2195}

![Normalized transcript levels of VEGF in regard to the type of ID herniation. ID herniation samples with protrusion exhibited an increased mRNA expression of VEGF compared with extruded discs (P=0.019, Mann-Whitney test). VEGF, vascular endothelial growth factor; ID, intervertebral disc.](MMR-15-04-2195-g02){#f3-mmr-15-04-2195}

###### 

Patient clinical characteristics.

  Characteristic                    No. of patients
  --------------------------------- ---------------------
  ID herniation group Age (years)   
    Mean (range)                    47.3 (27--68)
      20--39                        27
      40--59                        23
      \>60                          12
  Gender                            
    Male/female                     33/30
  Body mass index (BMI)             
    Mean (range)                    27.2 (21.07--33.05)
  Level of ID herniation            
    L3-L4                           11
    L4-L5                           24
    L5-S1                           28
  Type of herniation                
    Protrusion                      23
    Extrusion                       33
    Sequestration                     7
  Duration of symptoms              
    \<3 months                      15
    3--12 months                    20
    \>12 months                     28
  Pain intensity (VAS)              
    0--5                            18
    5--7                            14
    8--10                           31
  Employment                        
    Heavy/light                     36/27
  Smoking Habits                    
    Smokers/non-smokers             26/37
    \<10 cig per day                  6
    10- 20 cig per day                8
    \>20 cig per day                12
  Control group Age (years)         
    Mean (range)                    36.8 (20--46)
  Gender                            
    Male/female                     6/4
  Body mass index (BMI)             
    Mean (range)                    27.0 (21.9--33.0)
  Employment                        
    Heavy/light                     7/3
  Smoking Habits                    
    Smokers/non-smokers             4/6

###### 

Sequences of primers used for RT-qPCR.

  Gene         Primer pair sequence (5′→3′)   Annealing temperature (°C)   Product size (bp)
  ------------ ------------------------------ ---------------------------- -------------------
  IGF-1        CCTCCTCGCATCTCTTCTACCTGC       60                           166
               TGCTGGAGCCATACCCTGTG                                        
  FGF-2        CTGGCTATGAAGGAAGATGGA          55                           149
               TGCCCAGTTCGTTTCAGTG                                         
  TGF-Β        AAGGACCTCGGCTGGAAGTGC          62                           137
               CCGGGTTATGCTGGTTGTA                                         
  VEGF         ATGACGAGGGCCTGGAGTGTG          60                             91
               CCTATGTGCTGGCCTTGGTGAG                                      
  PDGF-A       ACACGAGCAGTGTCAAGTGC           55                             76
               CCTGACGTATTCCACCTTGG                                        
  PDGF-B       AGATCGAGATTGTGCGGAAG           52                             94
               CAGCTGCCACTGTCTCACAC                                        
  PDGF-C       GCCAGGTTGTCTCCTGGTTA           52                             86
               TGCTTGGGACACATTGACAT                                        
  PDGF-D       CCCAGGAATTACTCGGTCAA           52                           105
               ACAGCCACAATTTCCTCCAC                                        
  PDGF rec-A   TGGGAGTTTCCAAGAGATGG           52                             78
               TGTTCCTTCAACCACCTTCC                                        
  PDGF rec-B   GTGCTCACCATCATCTCCCT           52                             85
               ACTCAATCACCTTCCATCGG                                        
  GAPDH        GGAAGGTGAAGGTCGGAGTCA          60                           101
               GTCATTGATGGCAACAATATCCACT                                   

###### 

Growth factor mRNA expression.

  Expressed Gene   Control discs (n=10)   Herniated discs (n=63)   P-value^[a](#tfn1-mmr-15-04-2195){ref-type="table-fn"}^   Control discs (n=10)   Herniated discs (%) (n=63)   P-value^[b](#tfn2-mmr-15-04-2195){ref-type="table-fn"}^
  ---------------- ---------------------- ------------------------ --------------------------------------------------------- ---------------------- ---------------------------- ---------------------------------------------------------
  IGF              1.2637±0.961           11256.0652±1.12          NS                                                        5/10                   22/63 (34.9)                 NS
  FGF              0.0431±0.032           46.0385±38.749           NS                                                        4/10                   30/63 (47.6)                 NS
  TGF              1.1329±0.616           36.8798±13.531           NS                                                        9/10                   56/63 (88.8)                 NS
  VEGF             0.0003±0.001           9.9859±9.7546            NS                                                        5/10                   33/63 (52.3)                 NS
  PDGF-A           0.6554±0.613           24.7222±10.603           NS                                                        4/10                   31/63 (49.2)                 NS
  PDGF-B           4.5424±2.395           65.3348±52.903           NS                                                        10/10                  62/63 (98.4)                 NS
  PDGF-C           1.7382±0.427           121.2165±68.593          NS                                                        10/10                  63/63 (100)                  NS
  PDGF-D           3.2749±0.969           153.5597±97.695          NS                                                        10/10                  63/63 (100)                  NS
  PDGF rec-A       0.1241±0.052           25.8371±13.227           NS                                                        6/10                   32/63 (50.7)                 NS
  PDGF rec-B       0.0823±0.053           12.5163±5.361            NS                                                        4/10                   29/63 (46)                   NS

Mann-Whitney test

χ^2^ NS, non-significant. Quantitative data are presented as the means ± SEM, and are based on the expression status (expressed or not) in the control and herniated lumbar discs.

###### 

Spearman correlation tables demonstrating the co-expression profile of GFs in the group of herniated lumbar discs.

  Factor   Method              bFGF      IGF         PDGF-A   PDGF-B      PDGF-C      PDGF-D   PDGFRA      PDGFRB      TGF-b       VEGF
  -------- ----------------- ----------- ----------- -------- ----------- ----------- -------- ----------- ----------- ----------- -------
  bFGF     Spearman\'s rho   1.000                                                                                                 
           Sig. 2-tailed     .                                                                                                     
  IGF      Spearman\'s rho   0.644       1.000                                                                                     
           Sig. 2-tailed     **0.000**   .                                                                                         
  PDGF-A   Spearman\'s rho   0.136       0.181       1.000                                                                         
           Sig. 2-tailed     0.294       0.159       .                                                                             
  PDGF-B   Spearman\'s rho   −0.175      −0.132      0.038    1.000                                                                
           Sig. 2-tailed     0.171       0.301       0.767    .                                                                    
  PDGF-C   Spearman\'s rho   −0.119      −0.050      −0.101   0.546       1.000                                                    
           Sig. 2-tailed     0.354       0.700       0.436    **0.000**   .                                                        
  PDGF-D   Spearman\'s rho   −0.151      −0.069      −0.091   0.536       0.728       1.000                                        
           Sig. 2-tailed     0.239       0.590       0.480    **0.000**   **0.000**   .                                            
  PDGFRA   Spearman\'s rho   0.744       0.572       0.155    −0.031      0.002       −0.082   1.000                               
           Sig. 2-tailed     **0.000**   **0.000**   0.229    0.807       0.987       0.524    .                                   
  PDFGRB   Spearman\'s rho   0.845       0.654       0.212    −0.095      −0.057      −0.199   0.822       1.000                   
           Sig. 2-tailed     **0.000**   **0.000**   0.098    0.457       0.655       0.118    **0.000**   .                       
  TGF-b    Spearman\'s rho   0.376       0.325       0.164    0.060       0.201       0.168    0.287       0.365       1.000       
           Sig. 2-tailed     **0.002**   **0.009**   0.202    0.638       0.113       0.188    **0.022**   **0.003**   .           
  VEGF     Spearman\'s rho   0.886       0.557       0.077    −0.263      0.005       −0.054   0.680       0.770       0.477       1.000
           Sig. 2-tailed     **0.000**   **0.000**   0.552    **0.039**   0.967       0.676    **0.000**   **0.000**   **0.000**   .

Numbers in bold refer to statistically significant findings (correlations, 2-tailed). bFGF, basic fibroblast growth factor; IGF, insulin growth factor; PDGF, platelet derived growth factor; TGF, transforming growth factor; VEGF, vascular endothelial growth factor.

###### 

Spearman correlation tables demonstrating the co- expression profile of GFs in the group of control lumbar discs.

  Factor   Method            bFGF        IGF         PDGF-A      PDGF-B   PDGF-C   PDGF-D   PDGFRA      PDGFRB   VEGF     TGF-b
  -------- ----------------- ----------- ----------- ----------- -------- -------- -------- ----------- -------- -------- -------
  bFGF     Spearman\'s rho   1.000                                                                                        
           Sig. 2-tailed     .                                                                                            
  IGF      Spearman\'s rho   −0.076      1.000                                                                            
           Sig. 2-tailed     0.886       .                                                                                
  PDGF-A   Spearman\'s rho   −0.271      0.981       1.000                                                                
           Sig. 2-tailed     0.604       **0.001**   .                                                                    
  PDGF-B   Spearman\'s rho   −0.475      0.388       0.469       1.000                                                    
           Sig. 2-tailed     0.341       0.447       0.348       .                                                        
  PDGF-C   Spearman\'s rho   −0.636      0.644       0.749       0.632    1.000                                           
           Sig. 2-tailed     0.175       0.168       0.087       0.178    .                                               
  PDGF-D   Spearman\'s rho   −0.86       0.007       0.178       0.631    0.745    1.000                                  
           Sig. 2-tailed     **0.027**   0.989       0.735       0.179    0.089    .                                      
  PDGFRA   Spearman\'s rho   0.378       −0.422      −0.482      −0.677   −0.394   −0.310   1.000                         
           Sig. 2-tailed     0.460       0.405       0.333       0.140    0.440    0.550    .                             
  PDFGRB   Spearman\'s rho   0.338       −0.252      −0.308      −0.422   −0.057   −0.065   0.884       1.000             
           Sig. 2-tailed     0.512       0.630       0.553       0.405    0.914    0.903    **0.020**   .                 
  VEGF     Spearman\'s rho   0.096       −0.360      −0.367      −0.462   −0.214   −0.075   0.935       0.809    1.000    
           Sig. 2-tailed     0.857       0.483       0.474       0.356    0.683    0.887    **0.006**   0.051    .        
  TGF-b    Spearman\'s rho   −0.238      0.968       0.982       0.580    0.789    0.237    −0.504      −0.263   −0.392   1.000
           Sig. 2-tailed     0.650       **0.002**   **0.000**   0.227    0.062    0.652    0.307       0.614    0.442    .

Numbers in bold refer to statistically significant findings (correlations, 2-tailed). bFGF, basic fibroblast growth factor; IGF, insulin growth factor; PDGF, platelet derived growth factor; VEGF, vascular endothelial growth factor; TGF, transforming growth factor.
